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Spinal Cord Injury Induced Osteoporosis: Case Report and 
Current Literature 
Abdulai Bangura,1 Thomas Shuler,2 Lisa Wright,3 Anne Lake.4 
Abstract 
Background: Among the various etiologies of osteoporosis, spinal cord injury has a drastic progression of the disease, causing weekly bone loss. There is 
no definitive treatment for the prevention of osteoporosis in these individuals. This review illustrates the recent findings on the pathophysiology, treatment, 
and management of spinal cord injury-induced osteoporosis. Furthermore, we cover a case of a male patient who experienced severe bone loss after a 
spinal cord injury at the age of 21 years. The Case: We have a 57-year-old man with a history of AIS grade A spinal cord injury, level T11 with rod fixation 
from a motorcycle collision at age 21. His fracture history following the injury includes tibia, femur, and vertebral fractures. Bone mineral density imaging 
revealed notable T-scores ranging from -3.1 to -3.4 at the hip and femurs. Treatment plan consisted of teriparatide, dietary supplements, and physical 
therapy. Biomarkers from baseline to post one month of treatment revealed the following: procollagen type 1 N-terminal propeptide from 38 mcg/L to 70 
mcg/L and C-terminal telopeptide from 209 pg/mL to 88 pg/mL, representing an increased bone formation and decreased bone resorption, respectively. 
After two years, bone mineral density T-scores improved to -2.7 on the left and the patient was capable of standing for the first time with the assistance 
of a standing frame. Conclusion: Our case exemplified the progression of the disease and treatment options. A basis for the derivation of future innovative 
therapies has been covered. Favorable treatments and management are described in the review. 
 




Among the various etiologies of osteoporosis, spinal cord injury (SCI) 
has a drastic progression of the disease, causing weekly bone loss. This 
is due to a multifactorial and unfavorable set of consequences involving 
bone metabolism.1 Following bone peak mass at 30 years of age, men 
and women lose bone mineral density (BMD) at a rate of 0.3% and 0.5% 
per year, respectively. Post-menopausal women lose BMD at a rate of 
2% per year.2 However, individuals with SCI lose 1% of BMD per week.1 
Due to the significant amount of bone loss leading to osteoporotic 
fractures, individuals with SCI are at an increased risk for comorbidities 
including osteomyelitis, skin pressure ulcers from bracing and bedrest, 
and hypertensive crisis from autonomic dysreflexia.3,4 The National 
Spinal Cord Injury Statistical Center (NSCISC) reports an incidence of 
17,810 new SCI cases in the United States each year with a current 
prevalence that could reach 368,000 people. According to the NSCISC 
data sheets, both the incidence and prevalence have increased over 
the last couple years with the most common cause being motor vehicle 
accidents. Additional common causes are acts of violence (primarily 
gunshot wounds) and sports/recreational injuries.5,6 At this time, there 
is no definitive treatment for the prevention of osteoporosis in these 
individuals. We hope to establish the current pathophysiology to 
provide a basis for future innovative therapies. 
 
People with SCI are immediately challenged by the consequences of 
mechanical unloading, neural denervation with subsequent vascular 
dysregulation, and biomarker abnormalities. All of which contribute to 
either increased  bone  resorption,  decreased  bone  formation, or a 
combination of two. Mechanical unloading is noteworthy as it leads to 
a cascade of events that is expected to have the strongest association 
with bone loss.3 
 
In both human and animal studies, a decrease of mechanical loading 
on bone has been found to have a significant association with an 
increase in sclerostin protein synthesis and vice-versa.7,8 Sclerostin is 
encoded by the sclerostin gene (SOST) and it is expressed by many 
tissues, but primarily by osteocytes. Most recent literature has 
recognized sclerostin as the principal mediator of SCI osteoporosis.3 
Sclerostin inhibits the Wnt/β-catenin pathway, which is a vital 
component of bone formation.9 Furthermore, sclerostin increases the 
expression of receptor activator of nuclear factor kappa-Β ligand 
(RANKL) and decreases the expression of receptor activity of 
osteoprotegerin (OPG) which ultimately increases bone resorption.10  
 
Due to sclerostin’s strong correlation with mechanical unloading, it is 
a great contributor to SCI osteoporosis. Sclerostin demonstrates an 
inverse relationship with BMD within the first 5 years following SCI, with 
sclerostin levels increasing as BMD decreases. After 5 years, the 
relationship reverses into a positive relationship with sclerostin levels 
Highlights: 
 The most recent findings on the pathophysiology, treatment, and 
management of spinal cord injury induced osteoporosis. 
 A basis for the derivation of future innovative therapies for spinal 
cord injury induced osteoporosis. 
 Favorable treatments and management for best prognosis in spinal 
cord injury induced osteoporosis. 
Case Report  
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now decreasing as BMD levels continue to decrease.11 One study 
sampled men with chronic SCI (2+ years post injury) and as the number 
of years following the SCI increased, the levels of sclerostin and BMD 
decreased together. It is important to note that the duration of injury 
for the subjects ranged from 4.1 to 42.6 years. Their findings suggested 
that circulating sclerostin levels in chronic SCI is a potential indicator 
of osteoporosis severity.12 
 
Although mechanical unloading appears to be the point of attention, 
other factors impact SCI osteoporosis. As expected, there would be 
neural damage which reduces bone function. Sympathetic stimulation 
contributes to bone maintenance and it has been found that 
sympathetic denervation of bone in animal models revealed increased 
bone resorption and decreased bone mineralization. Furthermore, 
sympathetic denervation causes subsequent vascular dysregulation. 
The impairment of vascular regulation allows increased capillary and 
venous blood pooling which leads to increased intraluminal pressure. 
A potential consequence of local blood pooling is osteoclast formation.4 
For these reasons, sympathetic denervation and subsequent vascular 
dysregulation are potential contributors to osteoporosis in individuals 
with SCI. 
 
In addition to mechanical unloading and sympathetic denervation, 
biomarkers including vitamin D, parathyroid hormone (PTH), and fat, 
contribute to osteoporosis in individuals with SCI. Although the 
prevalence of vitamin D deficiency is high among the general 
population, people with SCI are still at an increased risk for vitamin D 
insufficiency or deficiency.13 In regards to PTH, the high activity of bone 
resorption following SCI induces hypercalcemia leading to the 
suppression of PTH synthesis.14 PTH has been found to suppress 
sclerostin levels in human and animal studies.15,16 Therefore, a decrease 
in PTH can subsequently lead to further bone loss by increasing 
sclerostin levels. Fat has also been found to affect bone maintenance 
in SCI individuals. Multiple studies have revealed that people with SCI 
have a greater percentage of body fat in comparison with matched age 
and sex controls, demonstrating a greater risk of obesity in people with 
SCI than in the general population.3  
 
It is established that fat has an osteoprotective effect on bone by way 
of increased mechanical loading which induces bone formation.17 
However, with SCI, muscle paralysis prevents mechanical loading and 
may disrupt this process. In addition, fat releases leptin which mainly 
regulates appetite and energy expenditure in the hypothalamus.18 
Leptin also has additional properties including bone formation 
regulation. Leptin can provide sympathetic inhibition to osteoblasts and 
suppress bone formation by way of beta-2-adrenergic receptors on the 
osteoblast cell surface.3 Leptin levels have been shown to be elevated 
in individuals with SCI in comparison with the general population.19 
Adiponectin is a hormone that is produced by adipocytes or fat cells. 
In both human and animal studies, increased levels of adiponectin have 
been associated with increased bone loss.3 One study revealed that 
adiponectin has an inverse relationship with BMD in individuals with 
chronic SCI. The same study revealed that when these individuals 
participated in walking activities, the inverse relationship was no longer 
found.20 However, research of the relationship between adiponectin and 
bone loss specifically in the SCI population is currently ongoing. 
Therefore, a deficiency of vitamin D or PTH, and an accumulation of fat 
could all potentially contribute to osteoporosis in individuals with SCI. 
 
We present a case of a male patient who experienced severe bone loss 





A 57-year-old man with a history of level T11, AIS grade A SCI with rod 
fixation from a motorcycle accident at age 21 was referred to our 
fracture liaison and bone health clinic for a bone health evaluation. The 
patient himself provided consent for his information to be included in 
publications. He is 5’10” with a body mass index (BMI) of 23.8. He has 
a 7.5 pack-years smoking history with cessation of smoking in 2015. His 
fracture history following the SCI included right tibia fracture, right 
femur fracture, and left femur fracture all of which were associated 
with the mechanical attempts of standing and therapy. There is no 
record of his treatment plan or laboratory results prior to his first visit 
at our bone health clinic. 
 
Investigation 
Physical examination was consistent with a T11 level paraplegia with 
anesthesia at the T12 dermatome and motor examination with flaccid 
lower extremity paralysis, and 2+ distal pulses. The left lower extremity 
had a slight knee contracture of 5 to 10 degrees. Bone density imaging 
referenced severe osteoporosis in the total hip and femoral neck 
bilaterally (Table 1). BMD imaging revealed the following notable T-
scores: right hip and right femoral neck [T-score -3.1], left hip and left 
femoral neck [T-score -3.4]. However, it is important to note that optimal 
leg positioning for BMD imaging was not achieved due to the patient’s 
limitations. Furthermore, radiological imaging represented diffuse bony 
demineralization of the left femur (Figure 1). Laboratory orders were 
ascertained for a baseline which included bone biomarkers for 
comparing with post treatment evaluations (Table 2). 
 
Table 1. Bone density imaging referenced severe osteoporosis in the total 
hip and femoral neck bilaterally. 
 
Component Value Comment 
BMD Spine (L1-L4) 1.282 
Could only scan L3-L4 due to 
hardware in L1-L2 
T-Score Spine (L1-L4) 0.4  
Z-Score Spine (L1-L4) 0.7  
BMD Right Hip 0.671  
T-Score Right Hip -3.1 Osteoporosis 
Z-Score Right Hip -2.2  
BMD Left Hip 0.622  
T-Score Left Hip -3.4 Osteoporosis 
Z-Score Left Hip -2.6  
BMD Mean Hip 0.674 
Unable to position legs 
optimally for scanning 
T- Score Mean Hip -3.3 osteoporosis 
Z-Score Mean Hip -2.4  
BMD Right Femoral Neck 0.671  
T-Score Right Femoral Neck -3.1 osteoporosis 
Z-Score Right Femoral Neck -2.2  
BMD Left Femoral Neck 0.622  
T-Score Left Femoral Neck -3.4 osteoporosis 
Z-Score Left Femoral Neck -2.6  
 
Table 2. Baseline and post-therapy biomarkers. 
 
Lab Reference range Baseline 1 month 
P1NP 30-110 mcg/L 38 mcg/L 70 mcg/L 
Vitamin D 30-100 ng/mL 26 ng/mL 50 ng/mL 
Alk Phos Bone 7.6-14.9 mcg/L 12.1 mcg/L  
CTX 87-345 pg/mL 209 pg/mL 88 pg/mL 
PTH 18.4-88.0 pg/mL 52.8 pg/mL  
Phosphorous 2.5-4.6 mg/dL 3.3 mg/dL  
Calcium 8.5-10.7 mg/dL 9.8 mg/dL 10.4 mg/dL 
Creatinine 0.5-1.4 mg/dL 0.46 mg/dL <0.38 mg/dL 
Ionized Calcium 1.13-1.32 mmol/L  1.19 mmol/L 
 
Management 
We considered the patient’s past history, imaging, and laboratory 
results to align the following treatment plan: teriparatide [rDNAorigin] 
injection once daily, vitamin D2 (50,000 iu’s) once weekly for 8 weeks, 
vitamin D3 (2000 iu’s) once daily, vitamin K2, and calcium citrate 600 
mg once daily. Additional supplements included magnesium citrate and 
creatine. Treatment medication was chosen based upon the goal of 
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standing frame. Treatment decisions were made based upon current 
available literature and shared decision making between the patient. 
Outpatient physical therapy was prescribed to promote resistance 
upper body training to help promote bone growth in addition to his use 
of teriparatide. The patient was also followed by physical medicine and 
rehabilitation with which a standing frame was attempted but not 
achieved. After one year of treatment, care was transferred to another 
fracture liaison and bone health clinic. At the new site, the patient 
continued with teriparatide for an additional year, which was then 
discontinued due to its black box warning. There is a theoretical risk of 
osteosarcoma when medicating with teriparatide for more than 2 years. 
Vitamin D3 supplementation was also continued, but at a greater dose, 
3000 iu’s once daily. While promoting bone formation with biologic 
measures, the mechanical goal of aligning the patient to a standing 
frame remained the same. 
 
Figure 1. Left knee x-ray (oblique, externally rotated). Diffuse bony 
demineralization reduces sensitivity of radiography for acute fracture. There 
is corticated deformity of the distal femur and proximal tibia from old, 




Notable biomarkers from baseline to post one month of treatment 
revealed the following: procollagen-1 N-terminal peptide (P1NP) from 
38 mcg/L to 70 mcg/L and C-terminal telopeptide (CTX) 209 pg/mL to 88 
pg/mL, representing an increased bone formation and decreased bone 
resorption, respectively. The patient’s symptoms regarding immobility 
and fracture risk remained the same at that time. After two years of 
treatment, there was improvement in BMD represented at the left 
femoral neck [T-score -2.7] and left total hip [T-score -2.7] which both 
improved from baseline [T-score -3.4] (Table 1). Furthermore, the 
patient was capable of utilizing a standing frame and stood for the first 
time since before his injury 38 years prior. 
 
Discussion 
Our case revealed improvement in osteoporosis labs and physical 
symptoms during a two-year course of treatment. Once labs and bone 
density tests have leveled, we would expect them to be at a steady 
state barring overall health change. We believe the improvement seen 
in our patient’s BMD was supported by prescribing teriparatide, 
supplementing vitamin D, and utilizing a standing frame. During the 
time of management, we were not informed of the International Society 
for Clinical Densitometry (ISCD) guidelines and did not utilize them. This 
patient could have also been a good candidate to consider the latest 
technology VirtuOst Stress Test due to the difficulty in patient 
positioning from his previous bone density imaging. VirtuOst Stress Test 
is a Food Drug Administration (FDA) cleared virtual stress test that 
assesses BMD, bone strength, and fracture risk. Bone density does not 
fully assess bone strength and quality. Factors such as diet, smoking 
status, alcohol use, are also important associated factors to evaluate in 
a patient with osteoporosis. In this patient’s case, we focused on a 
weight training program aligned with a physical therapist to promote 
body strength which over time had weakened in addition to providing 
mechanical load to the skeleton. 
 
Due to the black box warning on teriparatide, the patient’s medication 
was switched to denosumab, a monoclonal antibody against RANKL. The 
decision to transition to denosumab was extrapolated from the DATA-
switch study.21 There has since been an update to teriparatide’s label, 
removing the black box warning. The decision to resume teriparatide 
after two years is determined by clinical decision making and risk-
benefit considerations. Given the recent update regarding teriparatide, 
it is reasonable to evaluate the patient one year after denosumab to 
determine whether to consider a future return to an anabolic therapy 
such as teriparatide. It is important to accrue bone mass over time by 
structuring a sequence of pharmacologic therapy. 
 
If our patient’s future progression becomes similar to previous studied 
cases, then we should expect a cessation in lab and bone density test 
improvement and minimal or no improvement of symptoms. For these 
reasons, it is important to illustrate the most recent findings of the 
pathophysiology, treatment, and management of SCI osteoporosis to 
reference optimal care and provide a basis for the derivation of future 
innovative therapies. 
 
Although the pathophysiology of SCI osteoporosis has been distinctly 
outlined, the treatments’ efficacy remains limited.22 
 
Current Treatments 
An effective long-term treatment for SCI osteoporosis has not been 
established. Current treatment options include pharmacological and 
physical therapy interventions. Although there are no interventions 
which prevent or reverse SCI osteoporosis, bisphosphonates, a group 
of antiresorptive drugs, are the most common pharmacological 
treatment for bone loss prevention in these individuals. Unfortunately, 
bisphosphonates have mostly been shown to be effective within the 
first year post SCI.4 Studies have shown a 16.4% to 19.7% reduction in 
bone loss at the femoral neck and approximately 21% percent reduction 
in bone loss at the total hip when treating SCI osteoporosis with 
bisphosphonates within the first year.23 However, a single study 
revealed that a two year course of bisphosphonates following SCI 
reduces the risk of fracture for two years, but revealed no evidence of 
bone loss prevention following one year.3 Bisphosphonates aid in the 
prevention of acute bone loss following SCI, but have no effect on bone 
formation. Therefore, the effect of bisphosphonates is not substantial. 
This dilemma has encouraged further investigation for more desirable 
pharmacological treatments.  
 
Teriparatide (TPDT), a recombinant human parathyroid hormone has 
recently gained attention as the optimal pharmacological treatment. 
TPDT is one of the few approved anabolic pharmacological treatments 
for osteoporosis and can be effective up until 24 months.24 It has also 
shown efficacy in treatment of SCI osteoporosis demonstrating a 4.8% 
to 5.5% increase in spinal BMD from baseline to 12 months. 
Furthermore, TPDT revealed a 7.1% to 14.4% increase in spinal BMD 
from baseline to 24 months.25 Along with these current drug therapies, 
denosumab, a monoclonal antibody against RANKL has been shown to 
increase BMD in individuals with SCI induced osteoporosis as well.26 
 
Case Report  
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As for physical therapy interventions, weight-bearing exercises, 
functional electrical stimulation (FES), and whole-body vibration (WBV) 
have been used to improve osteoporosis by increasing BMD.3,4 As we 
discussed earlier, sclerostin levels decrease with mechanical loading. 
Therefore, an increase of bone formation should be expected to follow 
weight-bearing exercises. Mechanical loading in SCI is a considerable 
challenge given the immobile state of the person. However, this 
challenge has been approached with FES exercises. FES treatment 
achieves mechanical loading by allowing electrodes to stimulate 
paralyzed muscles and facilitate muscle contraction. FES exercises have 
not been proven to provide long-term efficacy.  
 
Whole body vibration (WBV) therapy also can achieve mechanical 
loading via mechanical vibration and is currently a potential treatment 
for bone formation in SCI. In fact, both human and animal studies have 
reported neurological function recovery with SCIs after WBV therapy.27,28 
The efficacy of WBV therapy on osteoporosis in SCI has not been 
thoroughly evaluated. However, one study was able to report an 




Additional potential treatments for SCI induced osteoporosis include 
romosozumab, abaloparatide, activin receptor blockers, and cathepsin-
K inhibitors. Romosozumab (ROMO) is a new anti-sclerostin drug that 
has revealed a significantly greater improvement in BMD and reduced 
fracture risk in comparison with teriparatide treatment in post-
menopausal women with osteoporosis.29 Although ROMO has not yet 
been approved for men due to serious cardiovascular side effect risks, 
it has shown promising results of BMD improvement in its phase III 
clinical trial.30 There is a lack of research on the effects of ROMO 
administration on the bone metabolism of the SCI population. 
 
Abaloparatide is a bone forming agent used to treat post-menopausal 
osteoporosis in women who have failed antiresorptive therapy or have 
a high risk of fracture. Abaloparatide usage reduces the risk of 
osteoporotic fractures and the prevalence of hypercalcemia in 
comparison with teriparatide. Furthermore, it is more cost effective 
than teriparatide.31 Again, there is a lack of research on the effects of 
abaloparatide administration on the bone metabolism of the SCI 
population. Not to mention, both romosozumab and abaloparatide have 
not yet been approved for males. Although romosozumab and 
abaloparatide have not proved their efficiency in SCI osteoporosis, they 
both remain potential pharmacological treatments.  
 
Additional but less effective potential treatments currently being 
reviewed are type II activin receptor (ActRIIA) blockers and cathepsin-K 
inhibitors. Up to date, the efficacy of ActRIIA blockade has not been 
reviewed in people with SCI. Cathepsin-K is a protease involved in bone 
catabolism and research unveiled early bone loss prevention in post-
menopausal women with cathepsin-K inhibitors.3 However, cathepsin-
K inhibitors have been found to increase the risk of stroke which led to 
the termination of its development, specifically odanacatib.32 Therefore, 
ActRIIA blockers and cathepsin-K inhibitors remain potential 
pharmacological treatments for SCI osteoporosis as well. 
Management 
As for management, serial dual-energy X-ray absorptiometry (DXA) 
scans are utilized concurrently with bone biomarker monitoring and 
correction.25 Up to now, the identification of clinical improvement via 
DXA scans has been limited due to the absence of an established 
guideline for SCI osteoporosis. Fortunately, the ISCD recently developed 
a task force to perform a multi-study review of the DXA scan’s role 
during various aspects of SCI osteoporosis management. This review 
allowed the ISCD to create their official position statement on BMD 
testing in SCI. The official position statement reports the following 
verbatim: 
“1. All adults with spinal cord injury resulting in permanent motor or 
sensory dysfunction should have a DXA scan of the total hip, proximal 
tibia, and distal femur as soon as medically stable. 
2.  In adults with SCI, total hip, distal femur and proximal tibia bone 
density should be used to diagnose osteoporosis, predict lower 
extremity fracture risk, and monitor response to therapy where 
normative data is available.  
3. Serial DXA assessment of treatment effectiveness among 
individuals with SCI should include evaluation at the total hip, distal 
femur, and proximal tibia, following a minimum of 12 months of 
therapy at 1- to 2-year intervals. Segmental analysis of total hip, distal 
femur and proximal tibia sub-regions from a whole-body scan should 
not be used for monitoring treatment.  
4. There is no established threshold BMD value below which weight-
bearing activities are absolutely contraindicated. BMD and clinical risk 
factors should be used to assess fracture risk prior to engaging in 
weight-bearing activities.”  
 
It is notable that the ISCD added the necessity of the person having 
sufficient turning radius for a manual or power wheelchair during the 
scan and that the chair must be equipped with a lift. Furthermore, 
focused areas containing artifacts should be recognized and should not 
be used for diagnosis, fracture risk assessment, or monitoring response 
to therapy. Some examples of artifacts include hardware, deformity, 
heterotopic ossification, contracture or movement (spasticity), or leg 
bag artifacts which prevent optimal position for scanning or limit the 
accuracy of the analysis.33   
 
The CTX is a marker of bone resorption (degradation) and the P1NP is 
a marker for bone formation.34 The biomarkers are used as a tool to 
help identify the appropriate recommendations for treatment along 
with other factors in the patient’s history such as previous osteoporosis 
treatment plan, comorbid conditions, among other factors. In the 
literature, in treatment of naïve patients, an increase in P1NP was a 
predictor of BMD at 12 months.35 There is no comparator to a median 




The findings in this case provide hope for bone health and strength in 
SCI patients as they continue to age with their disability. Newer 
anabolics, such as abaloparatide and romosozumab, have shown 
greater improvement than previous treatments in osteoporosis. We 
believe using optimal pharmacological agents, mechanical loading of 
the skeleton, and the ISCD guidelines will allow the best patient 
prognosis for the general population of SCI patients. The 
pathophysiology of spinal cord injury induced osteoporosis has been 
distinctly outlined. Our case exemplified progress that can be made 
with aggressive mechanical and biologic treatment. A basis for the 
derivation of future innovative therapies has been covered. Favorable 
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